EcoDrugPlus

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSDORG00000011513
Gene Symbol: GRIN2A
3 Cross references
295 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSDORG00000001560
Gene Symbol: GRIN2B
2 Cross references
334 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSDORG00000005317
Gene Symbol: GRIN2C
4 Cross references
318 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3a

Ensembl ID : ENSDORG00000011973
Gene Symbol: GRIN3A
4 Cross references
245 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3b

Ensembl ID : ENSDORG00000001134
Gene Symbol: GRIN3B
3 Cross references
289 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSDORG00000010122
Gene Symbol: GRIK1
3 Cross references
316 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSDORG00000015175
Gene Symbol: GRIK2
4 Cross references
333 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSDORG00000012002
Gene Symbol: GRIK3
4 Cross references
257 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSDORG00000009556
Gene Symbol: GRIK4
3 Cross references
262 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSDORG00000013438
Gene Symbol: GRIK5
3 Cross references
302 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSDORG00000000837
Gene Symbol: GRM2
4 Cross references
281 Possible Orthologues:

Glutamate Metabotropic Receptor 3

Ensembl ID : ENSDORG00000003905
Gene Symbol: GRM3
4 Cross references
213 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).